Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70154 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Nicole D Ferrante und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Algorithms, International Classification of Diseases. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, R01 CA206465, NCI NIH HHS.
Abstract (Originalsprache)
Background
The absence of validated methods to identify cholangiocarcinoma in real‐world data has prevented the conduct of pharmacoepidemiologic studies to evaluate determinants of this malignancy and examine the effectiveness of cholangiocarcinoma treatments.
Objective
To determine the accuracy of International Classification of Diseases for Oncology, Third Edition (ICD‐O‐3)‐based algorithms to identify cholangiocarcinoma and its subtype (intrahepatic or extrahepatic) within US Veterans Health Administration (VA) data.
Methods
We identified patients with cholangiocarcinoma ICD‐O‐3 diagnosis codes from January 2000–December 2019 in VA data. We developed eight algorithms utilizing ICD‐O‐3 histology codes for cholangiocarcinoma and further used ICD‐O‐3 topography codes for location (liver, intrahepatic bile duct, extrahepatic bile duct) plus maximum total bilirubin (≥ 3 mg/dL vs. < 3 mg/dL) within ± 45 days of diagnosis to identify cholangiocarcinoma subtype. Up to 80 patients were randomly selected for each algorithm, and their records were reviewed by two hepatologists. The positive predictive values (PPV) and 95% confidence interval (CI) for each algorithm were estimated.
Results
Among 2934 unique patients who met inclusion criteria, 574 were randomly selected for validation. All eight algorithms had high PPV for definite or probable cholangiocarcinoma, ranging from 83.8% (95% CI, 73.8%–91.1%) to 100.0% (95% CI, 95.5%–100.0%). Among three algorithms to identify intrahepatic cholangiocarcinoma, two had PPV ≥ 80% (range: 88.8% [95% CI, 79.7%–94.7%]‐91.3% [95% CI, 82.8%–96.4%]). Among five algorithms to identify extrahepatic cholangiocarcinoma, four had PPV ≥ 80% (range: 80.0% [95% CI, 69.6%–88.1%]‐94.0% [83.5%–98.7%]).
Conclusion
These algorithms can be used in future pharmacoepidemiologic studies to evaluate medications associated with intrahepatic or extrahepatic cholangiocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Center for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of…
- Division of Pathology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
- Yale School of Medicine, Yale Center for Clinical Investigation, New Haven, Connecticut, USA.
- VA Connecticut Health System, West Haven, Connecticut, USA.
ORCID-Profile: Nicole D Ferrante, Vincent Lo Re
Förderung
- NIAAA NIH HHS
- R01 CA206465
- NCI NIH HHS
- P01 AA029545
- T32 DK007740
- U24 AA020794
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Ferrante, N. D., Hubbard, R. A., Weinfurtner, K., Mezina, A. I., Newcomb, C. W., Furth, E. E., Bhattacharya, D., Njei, B., Taddei, T. H., Singal, A., Hoteit, M. A., Park, L. S., Kaplan, D., & Lo Re, V. (2025). Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70154
Vancouver
Ferrante ND, Hubbard RA, Weinfurtner K, Mezina AI, Newcomb CW, Furth EE, et al. Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70154
BibTeX
@article{Ferrante2025,
author = {Ferrante, Nicole D and Hubbard, Rebecca A and Weinfurtner, Kelley and Mezina, Anya I and Newcomb, Craig W and Furth, Emma E and Bhattacharya, Debika and Njei, Basile and Taddei, Tamar H and Singal, Amit and Hoteit, Maarouf A and Park, Lesley S and Kaplan, David and Lo Re, Vincent},
title = {Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70154}
}
EUVIMED